意大利代谢功能障碍相关性脂肪肝 (MASLD) 的经济影响。分析与展望。

IF 2.1 Q3 HEALTH CARE SCIENCES & SERVICES ClinicoEconomics and Outcomes Research Pub Date : 2024-10-24 eCollection Date: 2024-01-01 DOI:10.2147/CEOR.S472446
Enrico Torre, Sergio Di Matteo, Chiara Martinotti, Giacomo Matteo Bruno, Umberto Goglia, Gianni Testino, Alberto Rebora, Luigi Carlo Bottaro, Giorgio Lorenzo Colombo
{"title":"意大利代谢功能障碍相关性脂肪肝 (MASLD) 的经济影响。分析与展望。","authors":"Enrico Torre, Sergio Di Matteo, Chiara Martinotti, Giacomo Matteo Bruno, Umberto Goglia, Gianni Testino, Alberto Rebora, Luigi Carlo Bottaro, Giorgio Lorenzo Colombo","doi":"10.2147/CEOR.S472446","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Metabolic dysfunction-associated steatotic liver disease (MASLD) is a multisystem condition destined to become pandemic in the coming decades. This study aimed at evaluating the economic impact of MASLD in the Italian population from the Italian National Healthcare Service (NHS) perspective.</p><p><strong>Methods: </strong>The economic impact of the MASLD was assessed by developing a calculation model in Microsoft Excel<sup>®</sup> from the Italian NHS perspective, considering healthcare resources and direct costs. The target population was based on the prevalence data. Through a literature search, complications of MASLD were identified, including MASH, with relative risk of evolution into CC, DCC, HCC, T2DM, cardiovascular diseases, in particular AMI and stroke, CKD, and CRC. The differential impact between complication development in the population with MASLD and the same sample size population without-MASLD was evaluated. Differential risk data, mortality rates, and event unit costs were drawn from the published international literature. Frequency and cost data were applied to the total target population, the total annual costs and mortality data, referring to the two arms, were then calculated, and the differential value was obtained.</p><p><strong>Results: </strong>Based on an estimated 11,546,370 MASLD target population, an annual illness impact of €12,251,631,822 was calculated, corresponding to a difference of €7,731,674,054 compared with the same sample size without MASLD. Moreover, the MASLD population is expected to experience 13,438 additional deaths annually.</p><p><strong>Conclusion: </strong>The growing epidemiological impact of MASLD and its complications represent a huge economic burden for healthcare services worldwide. An integrated approach, including changes in lifestyle behaviors, will be the first step. Specific drugs for MASLD are not yet available; however, studies are underway, and combined pharmaceutical therapies may be an inevitable choice to achieve adequate control of MASLD and its complications.</p>","PeriodicalId":47313,"journal":{"name":"ClinicoEconomics and Outcomes Research","volume":null,"pages":null},"PeriodicalIF":2.1000,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11514691/pdf/","citationCount":"0","resultStr":"{\"title\":\"Economic Impact of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Italy. Analysis and Perspectives.\",\"authors\":\"Enrico Torre, Sergio Di Matteo, Chiara Martinotti, Giacomo Matteo Bruno, Umberto Goglia, Gianni Testino, Alberto Rebora, Luigi Carlo Bottaro, Giorgio Lorenzo Colombo\",\"doi\":\"10.2147/CEOR.S472446\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Metabolic dysfunction-associated steatotic liver disease (MASLD) is a multisystem condition destined to become pandemic in the coming decades. This study aimed at evaluating the economic impact of MASLD in the Italian population from the Italian National Healthcare Service (NHS) perspective.</p><p><strong>Methods: </strong>The economic impact of the MASLD was assessed by developing a calculation model in Microsoft Excel<sup>®</sup> from the Italian NHS perspective, considering healthcare resources and direct costs. The target population was based on the prevalence data. Through a literature search, complications of MASLD were identified, including MASH, with relative risk of evolution into CC, DCC, HCC, T2DM, cardiovascular diseases, in particular AMI and stroke, CKD, and CRC. The differential impact between complication development in the population with MASLD and the same sample size population without-MASLD was evaluated. Differential risk data, mortality rates, and event unit costs were drawn from the published international literature. Frequency and cost data were applied to the total target population, the total annual costs and mortality data, referring to the two arms, were then calculated, and the differential value was obtained.</p><p><strong>Results: </strong>Based on an estimated 11,546,370 MASLD target population, an annual illness impact of €12,251,631,822 was calculated, corresponding to a difference of €7,731,674,054 compared with the same sample size without MASLD. Moreover, the MASLD population is expected to experience 13,438 additional deaths annually.</p><p><strong>Conclusion: </strong>The growing epidemiological impact of MASLD and its complications represent a huge economic burden for healthcare services worldwide. An integrated approach, including changes in lifestyle behaviors, will be the first step. Specific drugs for MASLD are not yet available; however, studies are underway, and combined pharmaceutical therapies may be an inevitable choice to achieve adequate control of MASLD and its complications.</p>\",\"PeriodicalId\":47313,\"journal\":{\"name\":\"ClinicoEconomics and Outcomes Research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2024-10-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11514691/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ClinicoEconomics and Outcomes Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2147/CEOR.S472446\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"HEALTH CARE SCIENCES & SERVICES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ClinicoEconomics and Outcomes Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/CEOR.S472446","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0

摘要

背景:代谢功能障碍相关性脂肪性肝病(MASLD)是一种多系统疾病,注定将在未来几十年内流行。本研究旨在从意大利国家医疗服务体系(NHS)的角度评估代谢性脂肪肝对意大利人口的经济影响:方法:从意大利国家医疗服务体系(NHS)的角度出发,使用 Microsoft Excel® 建立计算模型,考虑医疗资源和直接成本,评估 MASLD 的经济影响。目标人群以发病率数据为基础。通过文献检索,确定了 MASLD 的并发症,包括 MASH,以及演变为 CC、DCC、HCC、T2DM、心血管疾病(尤其是急性心肌梗死和中风)、慢性肾脏病和 CRC 的相对风险。我们评估了并发症在 MASLD 患者和相同样本量的非 MASLD 患者中的不同影响。差异风险数据、死亡率和事件单位成本均来自已发表的国际文献。将频率和成本数据应用于全部目标人群,然后计算出两组人群的年度总成本和死亡率数据,并得出差值:结果:根据估计的 11,546,370 名 MASLD 目标人群,计算出每年的疾病影响为 12,251,631,822 欧元,与没有 MASLD 的相同样本量相比,差值为 7,731,674,054 欧元。此外,预计MASLD人群每年将增加13,438例死亡:MASLD及其并发症对流行病学的影响越来越大,给全球医疗服务带来了巨大的经济负担。包括改变生活方式行为在内的综合方法将是第一步。目前还没有治疗 MASLD 的特效药物;不过,相关研究正在进行中,联合药物疗法可能是充分控制 MASLD 及其并发症的必然选择。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Economic Impact of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Italy. Analysis and Perspectives.

Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a multisystem condition destined to become pandemic in the coming decades. This study aimed at evaluating the economic impact of MASLD in the Italian population from the Italian National Healthcare Service (NHS) perspective.

Methods: The economic impact of the MASLD was assessed by developing a calculation model in Microsoft Excel® from the Italian NHS perspective, considering healthcare resources and direct costs. The target population was based on the prevalence data. Through a literature search, complications of MASLD were identified, including MASH, with relative risk of evolution into CC, DCC, HCC, T2DM, cardiovascular diseases, in particular AMI and stroke, CKD, and CRC. The differential impact between complication development in the population with MASLD and the same sample size population without-MASLD was evaluated. Differential risk data, mortality rates, and event unit costs were drawn from the published international literature. Frequency and cost data were applied to the total target population, the total annual costs and mortality data, referring to the two arms, were then calculated, and the differential value was obtained.

Results: Based on an estimated 11,546,370 MASLD target population, an annual illness impact of €12,251,631,822 was calculated, corresponding to a difference of €7,731,674,054 compared with the same sample size without MASLD. Moreover, the MASLD population is expected to experience 13,438 additional deaths annually.

Conclusion: The growing epidemiological impact of MASLD and its complications represent a huge economic burden for healthcare services worldwide. An integrated approach, including changes in lifestyle behaviors, will be the first step. Specific drugs for MASLD are not yet available; however, studies are underway, and combined pharmaceutical therapies may be an inevitable choice to achieve adequate control of MASLD and its complications.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
ClinicoEconomics and Outcomes Research
ClinicoEconomics and Outcomes Research HEALTH CARE SCIENCES & SERVICES-
CiteScore
3.70
自引率
0.00%
发文量
83
审稿时长
16 weeks
期刊最新文献
Economic Impact of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Italy. Analysis and Perspectives. Evaluating Service Satisfaction and Sustainability of the Afya Health Insurance Scheme in Kuwait: An Exploratory Analysis [Letter]. Estimating Costs Associated with Adverse Events in Patients with Advanced Lung Cancer. Economic Burden, Length of Hospital Stay and Complication of Simultaneous versus Staged Bilateral Hip Arthroplasty: A Hospital Prospective Study. Cost Analysis of Pure Hypochlorous Acid Preserved Wound Cleanser versus Mafenide for the Irrigation of Burn Wounds.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1